<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01615302</url>
  </required_header>
  <id_info>
    <org_study_id>METC 10-1-082</org_study_id>
    <nct_id>NCT01615302</nct_id>
  </id_info>
  <brief_title>Is the Use of Blood Platelets Effective in the Treatment of Difficult Fistulas Related to the Anal Sphincter?</brief_title>
  <official_title>Use of Platelet Rich Plasma (PRP) as an Adjunct in the Treatment of High Peri-anal Fistulas.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biomet Nederland BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale:

      Closure of the internal opening is the most accepted standard procedure in the treatment of
      peri-anal fistulas. The mucosal advancement flap is considered as golden standard. In one out
      of the three patients mucosal flap repair fails. Possible causal factors are incomplete
      clearance of pus and debris, incomplete closure of the internal opening, inappropriate host
      response in patients with risk factors like smoking or diabetes. Platelet derived growth
      factors may facilitate closure of the internal opening, especially in patients with impaired
      wound healing.

      Objective:

      The use of autologous platelet rich plasma (PRP) as an adjunct to the staged mucosal
      advancement flap to achieve a better closure rate of complex peri-anal fistula's.

      Study design:

      Randomized, multicenter trial.

      Study population:

      Patients with complex cryptoglandular peri-anal fistula's.

      Intervention:

      Injection of PRP in the curretted fistula track under the mucosal flap.

      Main study parameters/endpoints:

        -  Recurrence rate

        -  Post-operative pain

        -  Continence

        -  Quality of life.

      Nature and extent of the burden and risks associated with participation, group relatedness:

      Because autologous blood is used, no extra risk are expected.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence of fistulas</measure>
    <time_frame>Assessed up to 104 weeks after operation</time_frame>
    <description>The surgeon or docter in the outpatient clinic will decide if there is a recurrent fistula or not.
In case of doubt a MRI will be made.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Assessed at 2 weeks after operation</time_frame>
    <description>Measured using the Visual Analogue Scale (VAS-score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Assessed at 2 weeks after operation</time_frame>
    <description>Measured using the SF-36v2 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence</measure>
    <time_frame>Assessed at 2 weeks after operation</time_frame>
    <description>Measured using the Vaizey score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Assessed at 4 weeks after operation</time_frame>
    <description>Measured using the Visual Analogue Scale (VAS-score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Assessed at 16 weeks after operation</time_frame>
    <description>Measured using the Visual Analogue Scale (VAS-score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Assessed at 24 weeks after operation</time_frame>
    <description>Measured using the Visual Analogue Scale (VAS-score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Assessed at 52 weeks after operation</time_frame>
    <description>Measured using the Visual Analogue Scale (VAS-score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Assessed at 104 weeks after operation</time_frame>
    <description>Measured using the Visual Analogue Scale (VAS-score)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Assessed at 4 weeks after operation</time_frame>
    <description>Measured using the SF-36v2 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Assessed at 16 weeks after operation</time_frame>
    <description>Measured using the SF-36v2 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Assessed at 24 weeks after operation</time_frame>
    <description>Measured using the SF-36v2 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Assessed at 52 weeks after operation</time_frame>
    <description>Measured using the SF-36v2 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Assessed at 104 weeks after operation</time_frame>
    <description>Measured using the SF-36v2 questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence</measure>
    <time_frame>Assesed at 4 weeks after operation</time_frame>
    <description>Measured using the Vaizey score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence</measure>
    <time_frame>Assessed at 16 weeks after operation</time_frame>
    <description>Measured using the Vaizey score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence</measure>
    <time_frame>Assessed at 52 weeks after operation</time_frame>
    <description>Measured using the Vaizey score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence</measure>
    <time_frame>Assessed at 24 weeks after operation</time_frame>
    <description>Measured using the Vaizey score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incontinence</measure>
    <time_frame>Assessed at 104 weeks after operation</time_frame>
    <description>Measured using the Vaizey score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Rectal Fistula</condition>
  <arm_group>
    <arm_group_label>Mucosa advancement flap</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Mucosa advancement flap + PRP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Platelet rich plasma added to the mucosa advancement flap</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Mucosa advancement flap</intervention_name>
    <description>Mucosa advancement flap will be performed at the starting point of the fistula in the rectum</description>
    <arm_group_label>Mucosa advancement flap</arm_group_label>
    <arm_group_label>Mucosa advancement flap + PRP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Platelet rich plasma (PRP)</intervention_name>
    <description>The PRP will be injected into the fistula, after the mucosa advancement flap was created.
For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP.</description>
    <arm_group_label>Mucosa advancement flap + PRP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Complex peri-anal fistula.

          -  Able to understand informed consent.

        Exclusion Criteria:

          -  Pregnancy

          -  Local malignancy

          -  Crohn's disease or Ulcerative colitis

          -  Traumatic or iatrogenic lesion

          -  Thrombocytopenia

          -  Splenomegaly

          -  Bleeding disorders

          -  Hematologic malignancies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephanie O. Breukink, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Cor G.M.I. Baeten, MD, PhD, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin W.A. Göttgens, MD</last_name>
    <phone>+31433876543</phone>
    <email>kevin.gottgens@mumc.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Refaja Ziekenhuis</name>
      <address>
        <city>Stadskanaal</city>
        <state>Groningen</state>
        <zip>9501 HE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephan J. van der Hagen, MD, PhD</last_name>
      <phone>+31599654654</phone>
      <email>sjvanderhagen@refaja.nl</email>
    </contact>
    <investigator>
      <last_name>Stephan J. van der Hagen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atrium Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <state>Limburg</state>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wim G. v. Gemert, MD, PhD</last_name>
      <phone>+31455766666</phone>
      <email>wgt01@atriummc.nl</email>
    </contact>
    <investigator>
      <last_name>Wim G. van Gemert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Maastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kevin W.A. Göttgens, MD</last_name>
      <phone>+31433876543</phone>
      <email>kevin.gottgens@mumc.nl</email>
    </contact>
    <investigator>
      <last_name>Stephanie O. Breukink, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kevin W.A. Göttgens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laurentius ziekenhuis</name>
      <address>
        <city>Roermond</city>
        <state>Limburg</state>
        <zip>6043 CV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeroen Heemskerk, MD, PhD</last_name>
      <phone>+31475382222</phone>
      <email>j.heemskerk@lzr.nl</email>
    </contact>
    <investigator>
      <last_name>Jeroen Heemskerk, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Amphia ziekenhuis</name>
      <address>
        <city>Breda</city>
        <state>Noord Brabant</state>
        <zip>4819 EV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Catharina ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>J.P. de Zoete, MD, PhD</last_name>
      <phone>+31402399111</phone>
      <email>jean-paul.d.zoete@cze.nl</email>
    </contact>
    <investigator>
      <last_name>J.P. de Zoete, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>van der Hagen SJ, Baeten CG, Soeters PB, van Gemert WG. Autologous platelet-derived growth factors (platelet-rich plasma) as an adjunct to mucosal advancement flap in high cryptoglandular perianal fistulae: a pilot study. Colorectal Dis. 2011 Feb;13(2):215-8. doi: 10.1111/j.1463-1318.2009.01991.x.</citation>
    <PMID>19575739</PMID>
  </reference>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 30, 2012</study_first_submitted>
  <study_first_submitted_qc>June 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2012</study_first_posted>
  <last_update_submitted>August 21, 2012</last_update_submitted>
  <last_update_submitted_qc>August 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rectal Fistula</keyword>
  <keyword>Peri-anal Fistula</keyword>
  <keyword>Platelet-Rich Plasma</keyword>
  <keyword>Mucosa advancement flap</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Rectal Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

